Pacira BioSciences (PCRX) Income from Discontinued Operations (2017 - 2020)

Pacira BioSciences has reported Income from Discontinued Operations for 4 years, with the latest figure at -$692000.0 in Q3 2020.

• On a quarterly basis, Income from Discontinued Operations rose 90.92% year-over-year to -$692000.0 in Q3 2020; TTM through Sep 2020 was -$6.0 million, a 51.13% increase from a year earlier, with the FY2018 full-year figure at -$1.6 million, up 67.87% from the prior year.
• Income from Discontinued Operations was -$692000.0 for Q3 2020 at Pacira BioSciences, up from -$1.4 million in the prior quarter.
• The five-year high for Income from Discontinued Operations was $3.7 million in Q1 2020, with the low at -$7.6 million in Q3 2019.
• Average Income from Discontinued Operations over 4 years is -$1.3 million, with a median of -$692000.0 recorded in 2020.
• The sharpest annual moves came in 2019 and 2020: Income from Discontinued Operations plunged 2001.85% in 2019, then jumped 398.55% in 2020.
• Over 4 years, Income from Discontinued Operations stood at -$114000.0 in 2017, then soared by 53.51% to -$53000.0 in 2018, then plunged by 14273.58% to -$7.6 million in 2019, then surged by 90.92% to -$692000.0 in 2020.
• The last three Income from Discontinued Operations figures came in at -$692000.0 (Q3 2020), -$1.4 million (Q2 2020), and $3.7 million (Q1 2020), per Business Quant data.